REMIT

The REMIT project is using an interdisciplinary One Health approach to examine the epidemiological, practical and social feasibility of human Rift Valley fever (RVF) Phase IIb or Phase III vaccine efficacy trials, exploring alternative case definitions, trial designs and statistical power.

Left, Team member preparing to sample cohort participants. Right, Dr Rostal presenting at the stakeholder meeting in Moshi.
  • We will develop and apply existing RVF virus (RVFV) epidemiological models to predict the locations, drivers, scale and stability of RVFV spillover to humans across East, West, and South Africa.
  • We will collect additional data in Tanzania, leveraging existing platforms and datasets to conduct longitudinal human and cattle sampling and examine the feasibility of using a livestock abortion monitoring system as an early warning system for RVFV.
  • We will collect additional data in The Gambia, including conducting a serosurvey in people associated with households in which we have already sampled livestock, and testing banked human serum samples for RVFV antibodies.
  • We will use simulations informed by synthesised evidence to provide guidance on vaccine efficacy trial feasibility, including where and when trials might be feasible.

We appreciate all the contributions of our partners and stakeholders.

Partners and stakeholders at our meeting in Moshi on August 26, 2025

This work is a collaboration that is led by Kilimanjaro Clinical Research Institute in partnership with One Health Research Consulting, the Tanzania Veterinary Laboratory Agency, MRC The Gambia, University of Pretoria, National Institute for Communicable Diseases, Ifakara Health Institute, University of Glasgow, University of Otago, Washington State University and Global Health Tanzania.

Partners that contributed to the work led by Kilimanjaro Clinical Research Institute.

This project is funded by CEPI.